FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070799947> ?p ?o ?g. }

• W2070799947 endingPage "405" @default.
• W2070799947 startingPage "405" @default.
• W2070799947 abstract "Cardiovascular (CV) disease is a major factor in mortality rates around the world and contributes to more than one-third of deaths in the US. The underlying cause of CV disease is atherosclerosis, a chronic inflammatory process that is clinically manifested as coronary artery disease, carotid artery disease, or peripheral artery disease. It has been predicted that atherosclerosis will be the primary cause of death in the world by 2020. Consequently, developing a treatment regimen that can slow or even reverse the atherosclerotic process is imperative. Atherogenesis is initiated by endothelial injury due to oxidative stress associated with CV risk factors including diabetes mellitus, hypertension, cigarette smoking, dyslipidemia, obesity, and metabolic syndrome. Since the renin-angiotensin-aldosterone system (RAAS) plays a key role in vascular inflammatory responses, hypertension treatment with RAAS-blocking agents (angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin II receptor blockers [ARBs]) may slow inflammatory processes and disease progression. Reduced nitric oxide (NO) bioavailability has an important role in the process of endothelial dysfunction and hypertension. Therefore, agents that increase NO and decrease oxidative stress, such as ARBs and ACEIs, may interfere with atherosclerosis. Studies show that angiotensin II type 1 receptor antagonism with an ARB improves endothelial function and reduces atherogenesis. In patients with hypertension, the ARB olmesartan medoxomil provides effective blood pressure lowering, with inflammatory marker studies demonstrating significant RAAS suppression. Several prospective, randomized studies show vascular benefits with olmesartan medoxomil: reduced progression of coronary atherosclerosis in patients with stable angina pectoris (OLIVUS); decreased vascular inflammatory markers in patients with hypertension and micro- (pre-clinical) inflammation (EUTOPIA); improved common carotid intima-media thickness and plaque volume in patients with diagnosed atherosclerosis (MORE); and resistance vessel remodeling in patients with stage 1 hypertension (VIOS). Although CV outcomes were not assessed in these studies, the observed benefits in surrogate endpoints of disease suggest that RAAS suppression with olmesartan medoxomil may potentially have beneficial effects on CV outcomes in these patient populations." @default.
• W2070799947 created "2016-06-24" @default.
• W2070799947 creator A5003822075 @default.
• W2070799947 date "2011-06-01" @default.
• W2070799947 modified "2023-10-10" @default.
• W2070799947 title "Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil" @default.
• W2070799947 cites W1542357680 @default.
• W2070799947 cites W156258132 @default.
• W2070799947 cites W1569851552 @default.
• W2070799947 cites W1719965740 @default.
• W2070799947 cites W180946569 @default.
• W2070799947 cites W18138333 @default.
• W2070799947 cites W1966790167 @default.
• W2070799947 cites W1970516435 @default.
• W2070799947 cites W1970600187 @default.
• W2070799947 cites W1972919038 @default.
• W2070799947 cites W1975781920 @default.
• W2070799947 cites W1983500969 @default.
• W2070799947 cites W1997300200 @default.
• W2070799947 cites W1997590138 @default.
• W2070799947 cites W2002138164 @default.
• W2070799947 cites W2002963575 @default.
• W2070799947 cites W2004898640 @default.
• W2070799947 cites W2014277051 @default.
• W2070799947 cites W2014652432 @default.
• W2070799947 cites W2014912220 @default.
• W2070799947 cites W2015319932 @default.
• W2070799947 cites W2016170994 @default.
• W2070799947 cites W2023768330 @default.
• W2070799947 cites W2024461046 @default.
• W2070799947 cites W2024946584 @default.
• W2070799947 cites W2034914625 @default.
• W2070799947 cites W2035210780 @default.
• W2070799947 cites W2035693691 @default.
• W2070799947 cites W2035960467 @default.
• W2070799947 cites W2036631090 @default.
• W2070799947 cites W2037360592 @default.
• W2070799947 cites W2038608848 @default.
• W2070799947 cites W2038970880 @default.
• W2070799947 cites W2039702404 @default.
• W2070799947 cites W2048587489 @default.
• W2070799947 cites W2048862063 @default.
• W2070799947 cites W2050758464 @default.
• W2070799947 cites W2052702970 @default.
• W2070799947 cites W2059350161 @default.
• W2070799947 cites W2060171803 @default.
• W2070799947 cites W2060465874 @default.
• W2070799947 cites W2063263408 @default.
• W2070799947 cites W2066512116 @default.
• W2070799947 cites W2075648762 @default.
• W2070799947 cites W2075700248 @default.
• W2070799947 cites W2075785558 @default.
• W2070799947 cites W2077739986 @default.
• W2070799947 cites W2077887669 @default.
• W2070799947 cites W2078600320 @default.
• W2070799947 cites W2080667729 @default.
• W2070799947 cites W2082283642 @default.
• W2070799947 cites W2089549133 @default.
• W2070799947 cites W2096626379 @default.
• W2070799947 cites W2114193904 @default.
• W2070799947 cites W2114722474 @default.
• W2070799947 cites W2117140855 @default.
• W2070799947 cites W2120179549 @default.
• W2070799947 cites W2120434113 @default.
• W2070799947 cites W2121795847 @default.
• W2070799947 cites W2122166221 @default.
• W2070799947 cites W2123799914 @default.
• W2070799947 cites W2128921112 @default.
• W2070799947 cites W2133293277 @default.
• W2070799947 cites W2138148166 @default.
• W2070799947 cites W2144528818 @default.
• W2070799947 cites W2145152082 @default.
• W2070799947 cites W2152043519 @default.
• W2070799947 cites W2164382299 @default.
• W2070799947 cites W2309975949 @default.
• W2070799947 cites W2324841714 @default.
• W2070799947 cites W2330005337 @default.
• W2070799947 cites W2341645956 @default.
• W2070799947 cites W2404071089 @default.
• W2070799947 cites W72197365 @default.
• W2070799947 cites W79675979 @default.
• W2070799947 cites W2083537035 @default.
• W2070799947 doi "https://doi.org/10.2147/vhrm.s20737" @default.
• W2070799947 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3141913" @default.
• W2070799947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21796255" @default.
• W2070799947 hasPublicationYear "2011" @default.
• W2070799947 type Work @default.
• W2070799947 sameAs 2070799947 @default.
• W2070799947 citedByCount "38" @default.
• W2070799947 countsByYear W20707999472012 @default.
• W2070799947 countsByYear W20707999472013 @default.
• W2070799947 countsByYear W20707999472014 @default.
• W2070799947 countsByYear W20707999472015 @default.
• W2070799947 countsByYear W20707999472016 @default.
• W2070799947 countsByYear W20707999472017 @default.
• W2070799947 countsByYear W20707999472018 @default.
• W2070799947 countsByYear W20707999472019 @default.
• W2070799947 countsByYear W20707999472020 @default.

• next